Post by miamianne67 on May 31, 2016 12:39:56 GMT
Miamianne says: Huntington's is one of the worst diseases out there, granted and this is terrific news.
30,000 estimated patients in USA...... CKD, on the other hand affects far more people .....just FYI
Corporate News, FDAGet it on Google
Teva Pharma (TEVA) Receives CRL from FDA for SD-809; No New Trials Requested
FREE Breaking News Alerts from StreetInsider.com
Jazz Pharma (JAZZ) Confirms Agreement to Acquire Celator Pharma (CPXX) for $30.25/Share, or ~$1.5B
Great Plains Energy (GXP) to Acquire Westar Energy (WR) in $12.2B Deal
Brent crude lower on strong Middle East oil output
Intercept Pharma (ICPT) Granted Accelerated FDA Approval of Ocaliva in PBC
May 31, 2016 7:02 AM EDT Tweet Share E-mail
Get Alerts TEVA Hot Sheet
Price: $51.66 --0%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.4%
EPS Growth %: -11.8%
Trade TEVA Now!
Join SI Premium – FREE
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for SD-809 (deutetrabenazine) tablets for the treatment of chorea associated Huntington disease (HD). This is the first deuterated product to be reviewed by the FDA. The FDA has asked Teva to examine blood levels of certain metabolites. These metabolites are not novel, and are the same seen in subjects who take tetrabenazine or deutetrabenazine. No new clinical trials have been requested.
“Teva will continue to work closely with the FDA to bring SD-809 to the market as quickly as possible,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We know that many people in the HD community are waiting for this new medicine. We understand there are very limited treatment options for HD patients and their families, hence we are accelerating the re-analysis process we were asked to conduct. We plan to submit our response to the CRL in Q3 2016."
HD is a rare and fatal neurodegenerative disorder caused by the death of nerve cells in the brain that affects about one in 7,000 – 10,000 people in western countries. Chorea—abnormal, involuntary writhing movements—is one of the most striking physical manifestations of this disease and it occurs in approximately 90% of patients at some point in the course of their illness.
In addition to HD, Teva’s programs for the development of SD-809 for the treatment of patients with tardive dyskinesia (TD) and Tourette syndrome (TS) are ongoing. Teva is currently conducting a Phase III efficacy and safety study in patients with moderate to severe TD known as AIM-TD (Addressing Involuntary Movements in Tardive Dyskinesia) and expects additional data from this study later in 2016, with regulatory submission to follow as planned. SD-809 has also been granted orphan drug designation for the treatment of TS in the pediatric population (defined as up to 16 years of age) and is planning further evaluation of SD-809 as a treatment for tics associated with TS.
30,000 estimated patients in USA...... CKD, on the other hand affects far more people .....just FYI
Corporate News, FDAGet it on Google
Teva Pharma (TEVA) Receives CRL from FDA for SD-809; No New Trials Requested
FREE Breaking News Alerts from StreetInsider.com
Jazz Pharma (JAZZ) Confirms Agreement to Acquire Celator Pharma (CPXX) for $30.25/Share, or ~$1.5B
Great Plains Energy (GXP) to Acquire Westar Energy (WR) in $12.2B Deal
Brent crude lower on strong Middle East oil output
Intercept Pharma (ICPT) Granted Accelerated FDA Approval of Ocaliva in PBC
May 31, 2016 7:02 AM EDT Tweet Share E-mail
Get Alerts TEVA Hot Sheet
Price: $51.66 --0%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.4%
EPS Growth %: -11.8%
Trade TEVA Now!
Join SI Premium – FREE
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for SD-809 (deutetrabenazine) tablets for the treatment of chorea associated Huntington disease (HD). This is the first deuterated product to be reviewed by the FDA. The FDA has asked Teva to examine blood levels of certain metabolites. These metabolites are not novel, and are the same seen in subjects who take tetrabenazine or deutetrabenazine. No new clinical trials have been requested.
“Teva will continue to work closely with the FDA to bring SD-809 to the market as quickly as possible,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We know that many people in the HD community are waiting for this new medicine. We understand there are very limited treatment options for HD patients and their families, hence we are accelerating the re-analysis process we were asked to conduct. We plan to submit our response to the CRL in Q3 2016."
HD is a rare and fatal neurodegenerative disorder caused by the death of nerve cells in the brain that affects about one in 7,000 – 10,000 people in western countries. Chorea—abnormal, involuntary writhing movements—is one of the most striking physical manifestations of this disease and it occurs in approximately 90% of patients at some point in the course of their illness.
In addition to HD, Teva’s programs for the development of SD-809 for the treatment of patients with tardive dyskinesia (TD) and Tourette syndrome (TS) are ongoing. Teva is currently conducting a Phase III efficacy and safety study in patients with moderate to severe TD known as AIM-TD (Addressing Involuntary Movements in Tardive Dyskinesia) and expects additional data from this study later in 2016, with regulatory submission to follow as planned. SD-809 has also been granted orphan drug designation for the treatment of TS in the pediatric population (defined as up to 16 years of age) and is planning further evaluation of SD-809 as a treatment for tics associated with TS.